H uman leukocyte antigens (HLAs) are among the most immunogenic humoral alloantigens and also represent the major target for organ transplant rejection by antibodies; the presence of anti-HLA antibodies in transplant recipients correlates to rejection of multiple organ types, including heart, kidney, lung, and liver. 1, 2 Preformed HLA antibodies can be a significant barrier to transplant; however, de novo anti-HLA antibodies formed over the course of an initial transplant can also result in graft failure. [3] [4] [5] Anti-HLA antibodies can also result in patients becoming refractory to transfusion of platelets, and in extreme cases, prevent platelet transfusion therapy as a viable approach to treating thrombocytopenia, leading to morbidity and mortality from hemorrhage. 6 Finally, anti-HLA antibodies in blood donors can be responsible for transfusion-related acute lung injury (TRALI).
HLAs are epitopes that differ between genetic variants of MHC Class I and/or MHC Class II, which are the major targets recognized by CD8+ and CD4+ T cells, respectively. Primary humoral alloimmunization can occur as a result of transplant and may also have been induced by previous transplantation. Pregnancy is also a major source of anti-HLA antibodies. 8 Finally, immune responses to environmental antigens can also lead to "natural anti-HLA antibodies" that are interpreted as cross-reacting with HLA; however, in such cases, effects on rejection are typically less severe. 9, 10 It has been well described that degree of mismatch correlates with likelihood of transplant rejection and also with the rate of alloimmunization. The observation that the more alloantigens to which one is exposed, the more likely one is to become alloimmunized is not surprising. However, this observation is equally consistent with at least two separate interpretations, leading to two distinct hypotheses: 1) that the relative immunogenicity of each alloantigen is an independent factor and that increased rates of alloantibodies are simply due to the aggregate risk of immunization to independent antigens; and 2) that there is a cooperative effect between HLA mismatches, such that the immune response against a particular alloantigen in isolation will be less than the immune response to the very same alloantigen in the context of other alloantigens. To the best of our knowledge, these two interpretations have not been rigorously explored.
In this report, we tested these hypotheses using a novel strain of mice in which the K d alloantigen was inserted into the antigen. This lack of response to the isolated alloantigen was overcome by increasing CD4+ T-cell precursor frequency, suggesting a mechanism by which increased mismatch augments immunogenicity of individual alloantigens through expanding the pool of alloantigen-specific CD4+ T cells. 
MATERIALS AND METHODS

Statistical analysis
Experiments presented in Fig. 1F were analyzed with a oneway analysis of variance (ANOVA) with a multiple comparisons posttest, comparing each experimental group against control B6, to determine significance. Experiments presented in Fig. 2 were analyzed with a repeated-measures two-way ANOVA with a multiple comparisons posttest, comparing each experimental group against control B6. Figure 3 was analyzed with a two-way ANOVA with a multiple comparisons posttest, comparing each experimental group against control B6. Significance was set at a p value of 0.05 or less (where ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, and n.s. = not significant).
RESULTS
Generation of a novel mouse with conditional expression of K d under natural regulatory elements
To test the ability of a single MHC I antigen to generate an alloimmune response, we generated a novel mouse (Con-K d ) with conditional expression of K d on a B6 background.
Homologous recombination was utilized to replace the endogenous K b gene with K d (Fig. 1A) . The targeting construct also contained a stop cassette consisting of four tandem repeats of a poly-A tail to terminate translation and was flanked by loxP sites, which are recognition sequences for Cre recombinase. -On" for the remainder of the paper. Although our knock-in approach was designed to maintain natural regulatory elements, the expression of K (Fig. 1D, left) . Mice express MHC I on both platelets and RBCs as well, albeit at significantly lower levels. 12 To maximize detection in the RBC and platelet compartments, staining was amplified using the FASER Kit (Miltenyi Biotec). -On mice, but at significantly lower levels than on BALB/c platelets (Fig. 1D, middle) . RBCs from ConK d -On mice had no detectable K d , unlike BALB/c RBCs that had low levels of detectable antigen (Fig. 1D, right) . Staining with antibodies to lineage specific markers was used to evaluate levels of K d expression on different (Fig. 3A) . The anti-K d alloantibody response was not an artifact of the peptide itself as no anti-K d was detected in B6 mice that received CFA/peptide immunization followed by B6 WBCs (Fig. 3A) with the experimental goal of increasing functional precursor frequencies of K d specific CD4+ T cells. (Fig. 4B ). Proliferation was antigen specific, as no CFSE dilution was observed when antigen-negative (B6) WBCs were infused ( and also the indirect pathway (i.e., recipient APCs can present peptide from K d on their MHC II to recipient T cells).
As such, in the experiments using adoptive transfer of TCR75, we cannot distinguish between stimulation of TCR75 by APCs of donor or recipient origin, either of which may have processed and presented K d on MHC II (I-A b ).
The same is the case with the peptide/CFA stimulation that primes a CD4+ T-cell response, although this latter case generates mature CD4+ T-cell help through the indirect pathway that would be boosted by either direct or indirect pathways upon WBC infusion. Although we cannot distinguish direct from indirect pathways herein, it is worth noting that we have previously reported that the direct pathway is not required for alloimmunization to MHC I alloantigens on transfused WBCs 15 K d expression through breeding with tissue specific CRE transgenics. Although outside the scope of the current report, this capacity will allow future studies on differential effects of WBC subsets. In summary, the data in this report are consistent with the interpretation that the immunogenicity of the same MHC I alloantigen is altered as a result of mismatch among other distinct MHC alleles. As with any model, it does not necessarily follow that the same phenomenology will be present in that being modeled (e.g., human biology). However, if such biology is present in humans, it may affect strategies for MHC mismatch in transfusion and/or transplantation. It is also worth noting that the strength of alloimmunity is also influenced by the murine strain combinations being used 27 and would likely also differ for humans across different HLA barriers. Thus, a personalized/precision medicine-based approach would likely have to guide such strategies.
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